Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study

Abstract

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200. mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. Design: Comparative double-blind randomized multicenter study in parallel groups. Setting: 200 patients of both genders of at least 50 years old with joint pain assessed as ≥30. mm on a visual analogical scale (VAS). Intervention: Collagen hydrolysate 1200. mg/day or placebo during 6 months. Main outcome measure: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-to-treat procedure. Results: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (. p